Author | Ronald de Wit, MD, PhD | OncLive

Author | Ronald de Wit, MD, PhD

Articles

Dr. de Wit on the AEs With Cabazitaxel in the CARD Trial in mCRPC

March 28, 2020

Video

Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses the adverse events (AEs) with cabazitaxel (Jevtana) in the phase III CARD trial in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. de Wit on Rationale for Phase III CARD Trial in Metastatic CRPC

October 24, 2019

Video

Ronald de Wit, MD, PhD, discusses the rationale for the randomized phase III CARD trial which showed a significant overall survival benefit with third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Dr. de Wit Discusses Findings With Pembrolizumab in NMIBC

November 17, 2018

Video

Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses findings with pembrolizumab (Keytruda) in non-muscle invasive bladder cancer.

x